Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (221-230 of 251) with videos related to

Pageof 26
Sort By:
Journal of Hepatology|April 17, 2022
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinomaSamuel Chuah, Joycelyn Lee, Yuan Song, et al.
Journal for Immunotherapy of Cancer|March 9, 2026
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancersChanghoon Yoo, Carles Fabregat-Franco, Chia-Chi Lin, et al.
Liver Cancer|April 21, 2025
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific CountriesChoong-Kun Lee, Changhoon Yoo, Jung Yong Hong, et al.
Hepatobiliary Surgery and Nutrition|June 11, 2026
Does neoadjuvant therapy reduce pancreatic fistula after pancreatoduodenectomy and distal pancreatectomy?-a systematic review and meta-analysisSandro Hügli, Victor Lopez-Lopez, Sarvar Abdurakhmonov, et al.
Annals of Surgical Oncology|April 5, 2023
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic ReviewDilmurodjon Eshmuminov, Botirjon Aminjonov, Russell F Palm, et al.
Liver Cancer|May 16, 2024
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in LenvatinibMassimo Iavarone, Eleonora Alimenti, Toshifumi Tada, et al.
Journal of the National Cancer Institute|July 13, 2026
Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysisVictor Lopez-Lopez, Tanja Hasse, Philipp Houben, et al.
Journal of Pathology and Translational Medicine|July 19, 2024
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSPMiso Kim, Hyo Sup Shim, Sheehyun Kim, et al.
Cancer Research and Treatment|December 1, 2023
Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSPMiso Kim, Hyo Sup Shim, Sheehyun Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Pageof 26

Showing results (221-230 of 251) with videos related to

Sort By:
Pageof 26
Journal of Hepatology|April 17, 2022
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinomaSamuel Chuah, Joycelyn Lee, Yuan Song, et al.
Journal for Immunotherapy of Cancer|March 9, 2026
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancersChanghoon Yoo, Carles Fabregat-Franco, Chia-Chi Lin, et al.
Liver Cancer|April 21, 2025
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific CountriesChoong-Kun Lee, Changhoon Yoo, Jung Yong Hong, et al.
Hepatobiliary Surgery and Nutrition|June 11, 2026
Does neoadjuvant therapy reduce pancreatic fistula after pancreatoduodenectomy and distal pancreatectomy?-a systematic review and meta-analysisSandro Hügli, Victor Lopez-Lopez, Sarvar Abdurakhmonov, et al.
Annals of Surgical Oncology|April 5, 2023
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic ReviewDilmurodjon Eshmuminov, Botirjon Aminjonov, Russell F Palm, et al.
Liver Cancer|May 16, 2024
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in LenvatinibMassimo Iavarone, Eleonora Alimenti, Toshifumi Tada, et al.
Journal of the National Cancer Institute|July 13, 2026
Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysisVictor Lopez-Lopez, Tanja Hasse, Philipp Houben, et al.
Journal of Pathology and Translational Medicine|July 19, 2024
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSPMiso Kim, Hyo Sup Shim, Sheehyun Kim, et al.
Cancer Research and Treatment|December 1, 2023
Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSPMiso Kim, Hyo Sup Shim, Sheehyun Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Pageof 26